

Small Interfering RNAs:

*A Revolutionary Tool
for the Analysis of Gene
Function and Gene Therapy*

The ability of double-stranded RNA (dsRNA) to silence the expression of genes has been the focus of many studies in C. elegans and D. melanogaster. More recent research has looked for evidence of RNAi-mediated gene suppression in other model organisms. Now there is excitement that RNAi-based methodologies will allow for the rapid assessment and validation of proteins as potential drug targets. Additionally, we might now be standing on the edge of fundamentally new approaches to gene therapy as conducted through RNAi-mediated suppression of mutated genes.

RNA interference (RNAi) represents an evolutionarily conserved cellular defense for controlling the expression of foreign genes in most eukaryotes including humans. RNAi is triggered by double-stranded RNA (dsRNA) and causes sequence-specific mRNA degradation of single-stranded target RNAs homologous in response to dsRNA. The mediators of mRNA degradation are small interfering RNA duplexes (siRNAs), which are produced from long dsRNA by enzymatic cleavage in the cell. siRNAs are approximately twenty-one nucleotides in length, and have a base-paired structure characterized by two-nucleotide 3'-overhangs. Chemically synthesized siRNAs have become powerful reagents for genome-wide analysis of mammalian gene function in cultured somatic cells. Beyond their value for validation of gene function, siRNAs also hold great potential as gene-specific therapeutic agents.

■ Thomas Tuschl¹ and Arndt Borkhardt²

¹Department of Cellular Biochemistry, Max-Planck-Institute for Biophysical Chemistry, D-37077 Goettingen, Germany

²Children's University Hospital, Pediatric Hematology and Oncology, 35392 Giessen, Germany

INTRODUCTION

When viruses infect eukaryotic cells, or when transposons and transgenes are randomly integrated into host genomes, dsRNA is frequently produced from the foreign genes. Most eukaryotes, including humans, possess an innate cellular immune surveillance system that specifically responds to the presence of dsRNA and activates processes that act post-transcriptionally to silence the expression of the interloping genes (1–4). This mechanism is now commonly referred to as RNA interference or RNAi (5). During RNAi, long transcripts of dsRNA are rapidly processed into small interfering RNAs (siRNAs), which represent RNA duplexes of specific length and structure that finally guide sequence-specific degradation of mRNAs homologous in sequence to the siRNAs (6, 7). The sequencing of the human genome has created an urgent need to ascertain efficiently the function of novel genes and to validate targets for drug discovery. Indeed, the rapid translation of the genomic DNA sequence information into therapeutic strategies for many common maladies—particularly infectious, cardiovascular, neoplastic, and neurological diseases—would be highly desirable. siRNAs may be the best tools for target validation in biomedical research today, because of their exquisite specificity, efficiency and endurance of gene-specific silencing. siRNAs are probably also suitable for the design of novel gene-specific therapeutics by directly targeting the mRNAs of disease-related genes.

The transfection of siRNAs into animal cells results in the potent, long-lasting post-transcriptional silencing of specific genes (8, 9). siRNA-mediated gene silencing is particularly useful in somatic mammalian cells, because these cells mount an additional, sequence-nonspecific innate immune response (i.e., responding with interferon-mediated defenses) when exposed to dsRNA greater than thirty base pairs, therefore prohibiting the application of longer dsRNAs (10). siRNAs are extraordinarily effective at lowering the amounts of targeted RNA—and by extension proteins—frequently to undetectable levels. The silencing effect is long lasting, typically several days, and extraordinarily specific, because one nucleotide mismatch between the target RNA and the central region of the siRNA is frequently sufficient to prevent silencing (6, 7, 11, 12). siRNAs can be rapidly synthesized and are now broadly available for the analyses of gene function in cultured mammalian cells. Similar to antisense oligonucleotide technology (13), the use of siRNAs also holds great promise for the application of gene-specific therapies in treating acute diseases such as viral infection, cancer, and, perhaps, acute inflammation.

THE MECHANISM OF dsRNA INTERFERENCE

A schematic illustration shows the mechanism of RNAi (Figure 1). The key enzyme required for processing of long dsRNAs to siRNA duplexes is the RNase III enzyme Dicer, which was characterized in extracts prepared from insect cells, *C. elegans* embryos, and




Figure 1. A model for RNA interference. dsRNA is processed to 21- to 23-nt siRNA duplexes by Dicer RNase III and possible other dsRNA-binding factors. The siRNA duplexes are incorporated into a siRNA-containing ribonucleoprotein complex (siRNP) (21) becoming the RNA-induced silencing complex (RISC) endonuclease, which targets homologous mRNAs for degradation. AGO2 and yet to be characterized proteins are thought to be required for RISC formation. The RISC mediates sequence-specific target RNA degradation. In plants and nematodes, targeted RNAs might also function as templates for double-strand RNA synthesis giving rise to transitive RNAi (24, 80–83), either through siRNA-primed dsRNA synthesis or through unprimed synthesis from aberrant RNA (which could represent the cleaved target RNA). In mammals or in fruitfly, however, RdRP genes have yet been identified, and the major mechanism of siRNA action is believed to be endonucleolytic target RNA cleavage guided by siRNA-protein complexes (RISC).

mouse cells (14–16). Dicer contains an N-terminal RNA helicase domain, a Piwi, Argonaute, Zwillie/Pinhead (PAZ) domain (17), two RNase III domains, and a C-terminal dsRNA-binding motif. The PAZ domain is also present in Argonaute proteins, whose genes represent a poorly characterized family present in dsRNA-responsive organisms. Argonaute1 (AGO1) and Argonaute2 (AGO2), two of the five Argonaute proteins of *D. melanogaster*, appear to be important for forming the mRNA-degrading sequence-specific endonuclease complex, also referred to as the RNA-induced silencing complex (RISC) (18, 19). Dicer and AGO2 appear to interact in *D. melanogaster* Schneider 2 (S2) cells, probably through their PAZ domains; however, RISC and Dicer activity are separable, and RISC is unable to process dsRNA to siRNAs, suggesting that Dicer is not a component of RISC (18, 20). Possibly, the interaction between Dicer and AGO2 facilitates the incorporation of siRNA into RISC (20). The endonucleolytic subunit of RISC remains to be identified.

siRNA duplexes produced by the action of Dicer contain 5'-

TABLE 1. siRNA-MEDIATED SILENCING IN CELL LINES

Cell line	Tissue origin	Reference
A-431	human epidermoid carcinoma	(23)
A549	human lung carcinoma	(72)
BV173	human B-precursor leukemia	(77)
C-33A	human papilloma virus negative cervical carcinoma	(46)
CA46	human Burkitt's lymphoma	(77)
Caco2	human colon epithelial cells	(61)
CHO	Chinese hamster ovary	(23)
COS-7	African green monkey kidney	(9)
F5	rat fibroblast	(32)
H1299	human nonsmall cell lung carcinoma	(46)
HaCaT	human keratinocyte cell	(12)
HEK 293	human embryonic kidney	(9)
HeLa	human papilloma virus positive cervical carcinoma	(9)
Hep3B	human hepatocellular carcinoma	(64)
HUVEC	human umbilical vein endothelial cells	(54)
IMR-90	human diploid fibroblast	(41)
K562	human chronic myelogenous leukemia, blast crisis	(77)
Karpas 299	human T-cell lymphoma	(77)
MCF-7	human breast cancer	(84)
MDA-MB-468	human breast cancer	(84)
MV-411	human acute monocytic leukemia	(77)
NIH/3T3	mouse fibroblast	(9)
P19	mouse embryonic carcinoma	(42)
SD1	human acute lymphoblastic leukemia	(77)
SKBR3	human breast cancer	(23)
U2OS	human osteogenic sarcoma cell	(59)

phosphates and free 3'-hydroxyl groups. The central base-paired region is flanked by two-to-three nucleotides of single-stranded 3'-overhangs (6). The 5'-phosphate termini of siRNAs is essential for guiding mRNA degradation (21). Nevertheless, for their practical application in gene targeting experiments, siRNAs may be used without 5'-phosphate termini because a kinase activity in the cell rapidly phosphorylates the 5' ends of synthetic siRNA duplexes (9, 21, 22). Under certain circumstances (e.g., injection experiments in *D. melanogaster*), 5'-phosphorylated siRNA duplexes may have slightly enhanced properties as compared to 5'-hydroxyl siRNAs (22). In gene targeting experiments using human HeLa cells, no differences in siRNA-mediated "knockdown" of gene expression were observed, as a function of 5'-phosphorylation (23). Furthermore, a cell line that is unable to utilize synthetic 5'-hydroxyl siRNAs for RNAi has not been encountered (for cell lines supporting RNAi see Table 1).

In *C. elegans*, introduction of approximately 300 bp dsRNA corresponding to a segment of the targeted gene may also give rise to the phenomenon of transitive RNAi (24). Transitive RNAi is characterized by the spreading of silencing outside of the region targeted by the initiator dsRNA. Presumably, targeted mRNA serves as template for RNA-dependent RNA polymerase (RdRP) and forms new dsRNA that is processed by Dicer. Thus, secondary

siRNAs are generated that may cleave the mRNA outside of the region targeted by the ancestral dsRNA. Although this appears to have important implications for RNAi-based analysis of gene function because silencing may spread between genes that share highly homologous sequences, phenotypic analysis of a large set of silenced genes in *C. elegans* suggests that transitive RNAi between naturally occurring homologous gene sequences is probably of no major concern (25, 26). It was also proposed that siRNAs might prime novel dsRNA synthesis; however, it should be pointed out that siRNAs, in comparison to longer dsRNAs, are extremely poor initiators of gene silencing in *C. elegans* (27, 28). Biochemical evidence for RdRP activity in *D. melanogaster* was recently reported (29), although genes encoding classical RdRP activity appear to be lacking from the *D. melanogaster* genome. Despite the beauty of the suggested model in *D. melanogaster*, which hypothesizes that siRNAs function as primers for target-RNA-dependent dsRNA synthesis, thus leading to amplification of the silencing signal (29), biochemical evidence for the spreading of gene silencing outside of regions targeted by dsRNAs has not been observed in other model systems (6, 12, 23, 30, 31). Rather, the predominant pathway of gene silencing appears to be siRNA-mediated target mRNA degradation by RISC formation, which may

also act catalytically. Similar to the situation in *D. melanogaster*, genes encoding RdRPs have not been identified in mammals. Therefore it is important to remember that the mechanisms of silencing differ between different species.

APPLICATION OF siRNAs IN SOMATIC MAMMALIAN CELLS

siRNAs have brought reverse genetics to mammalian cultured cells, and have made large-scale functional genomic analysis a realistic possibility (32). Standard cell lines provide starting points for mammalian functional screens because siRNAs can be effectively delivered by electroporation or cationic liposome-mediated transfection (11, 23). For small scale-applications, the microinjection of siRNAs may represent an alternative method. Technical problems that result from low transfection efficiencies may be partially overcome by using cell sorting protocols, such as after the transfection of siRNAs together with sorting markers such as GFP-expression plasmids. Alternatively, siRNAs that target cell surface marker proteins may be co-transfected, and the reduced expression of the co-targeted cell surface marker could then be used to identify specific cell populations by cell sorting.

An obvious prerequisite for the application of siRNAs for validation and therapeutic applications is the need for functional




Figure 2. Methods for the delivery of siRNAs to somatic mammalian cells. (A) Synthetic 21-nt siRNA duplex prepared by chemical synthesis (23) aligned to a target mRNA. Target regions are selected such that siRNA sequences may contain uridine residues in the 2-nt overhangs. Uridine residues in the 2-nt 3'-overhang can be replaced by 2'-deoxythymidine without loss of activity, which significantly reduces costs of RNA synthesis and may also enhance nuclease resistance of siRNA duplexes when applied to mammalian cell (7). (B) Plasmid-based expression of short hairpin loops which give rise to siRNAs in vivo (11). The polymerase III promoter of H1 RNA (human RNase P RNA) drives the transcription of a nineteen-base-pair/nine-nucleotide-loop RNA hairpin. The transcription is terminated by the encounter of a polythymidine tract (T5) after the incorporation of two to three uridine residues encoded by the T5 element. Northern blot analysis showed that the hairpin RNAs were processed to siRNAs.

RNAi machinery within the targeted cells or tissue to bind to siRNAs and mediate mRNA degradation. In order to assay for the activity of this ribonucleoprotein complex in cells, a reporter assay was developed (9, 23). Plasmids coding for firefly and sea-pansy luciferase are transfected together with control or target-specific (i.e., luciferase) siRNAs into cells, and the relative luminescence of target versus control luciferase activity is measured.

siRNAs have been used to identify cytoskeletal proteins that are essential for cell growth (32). Even the targeting of non-essential genes resulted in cellular phenotypes that were identical to phenotypes previously observed in cells derived from transgenic knockout mice (32), illustrating the value of siRNA methodology for the analysis of mammalian gene function.

In certain situations, several-hundred-base-pair long dsRNA represents an alternative to siRNAs. Long dsRNA effectively silences genes expressed in insect cells (18, 33–35) and in embryonic mammalian cells that have not yet established the interferon system (15, 36–39). However, undifferentiated cells,




Figure 3. Scheme of the translocation t(9;22) in leukemia. The BCR-ABL fusion mRNA provides a leukemia-specific target that can be cleaved by siRNAs.

such as embryonic stem (ES) cells or P19 teratocarcinoma cells, are difficult to work with because these progenitor cells are often poorly transfectable, making cell sorting prior to phenotypic analysis necessary (15).

Until recently, the application of siRNAs in somatic cells was restricted to the delivery of chemically or enzymatically synthesized siRNAs (9, 40–42) (Figure 2A), but methods for intracellular expression of small RNA molecules have now been developed. Endogenous delivery is possible by inserting DNA templates for siRNAs into RNA polymerase III (pol III) transcription units, which are based on the sequences of the natural transcription units of the small nuclear RNA U6 or the human RNase P RNA H1. Two approaches are available for expressing siRNAs: 1) The sense and antisense strands constituting the siRNA duplex are transcribed from individual promoters (42–44), or 2) siRNAs are expressed as fold-back stem-loop structures that give rise to siRNAs after intracellular processing by Dicer (11, 41, 42, 45, 46) (Figure 2B). The transfection of cells with plasmids that encode siRNAs, therefore, represents an alternative to direct siRNA transfection. Stable expression of siRNAs may facilitate certain applications such as the functional characterization of non-essential gene products in synthetic lethality screens or the construction of combinatorial libraries useful for loss-of-function screening in microarray assays (47). The insertion of siRNA expression cassettes into (retro)viral vectors will also enable the targeting of primary cells refractory to transfection or electroporation of plasmid DNA.

The function of several genes in cultured somatic mammalian cells have been analysed using siRNAs. The human vacuolar sorting protein Tsg101 was thus identified as essential for HIV-1 but not MLV budding (48). The reintroduction of a Tsg101-

expressing plasmid that encoded Tsg101 mRNA with silent mutations at the siRNA-targeting site restored the HIV-1 budding defect. siRNA-mediated depletion of endogenous targets and the re-introduction of siRNA-resistant rescue constructs (30) will become important for the analysis of protein function much like the complementation analyses used in traditional yeast genetic research. In other instances, siRNAs were applied for studying the role of proteins involved in DNA damage response and cell cycle control (11, 49–53), general cell metabolism (54–56), signaling (57–59), cytoskeleton and its rearrangement during mitosis (32, 44, 60), membrane trafficking (61, 62), transcription (63), and DNA methylation (64). These various examples reported by independent investigators illustrate the robustness of the siRNA gene silencing technology.

However, variations do exist in the efficiency of siRNAs to target the same genes (12, 23, 32). Our experience in targeting many different genes suggests that, on average, between seventy to ninety percent of randomly chosen siRNAs are able to reduce target gene expression by more than eighty percent. Some genes, encoding extremely abundant and extremely stable proteins (e.g., vimentin), may be more difficult to silence, and the probability for finding efficacious siRNAs may be lower (23, 32). Nonetheless, difficulty in depleting the most abundant proteins does not appear to compromise the value of this new transient gene silencing technology.

siRNAs AS NOVEL THERAPEUTIC PLATFORM TECHNOLOGY

siRNAs are highly sequence-specific reagents and discriminate between single mismatched target RNA sequences (7, 11), and may represent a new avenue for gene therapy. The expression of mRNAs coding for mutated proteins, which give rise to dominant genetic disorders and neoplastic growth, might be decreased or blocked completely by specific siRNAs.

With respect to targeting viral gene products expressed in virus-infected cells, it is possible that infectious mammalian viruses could express inhibitors of RNAi similar to those identified in plant and insect viruses (65–71). Because viral inhibitors of the mammalian RNAi machinery have not yet been described, it seems feasible that the application of siRNAs could extend our understanding of viral protein function and viral life cycle. Bitko and Barik successfully used siRNAs to silence genes expressed from respiratory syncytial virus

(RSV) (72), a negative strand RNA virus that causes sometimes severe respiratory disease, especially in neonates and infants. They also demonstrated that siRNAs do not induce interferon-mediated responses, by showing the absence of phosphorylation of the translation factor eIF-2 α . Although mRNAs transcribed from the viral genome were effectively silenced and viral replication was inhibited, it was not possible to cleave the viral genomic or antigenomic RNA because of its chromatin-like condensed structure. Lee et al. recently reported effective siRNA-mediated degradation of HIV-1 *rev* transcripts in a cell assay by co-transfection of proviral DNA and siRNA expression vectors, thus raising the possibility that siRNAs may become useful to treat HIV infection (43).

In leukemias and lymphomas—the most frequent cancers in childhood—oncogene activation frequently occurs through reciprocal chromosomal translocations. These translocations lead to juxtaposition of gene segments normally found on different chromosomes, and the creation of a composite gene. The prototype of such a translocation is the generation of the Philadelphia chromosome by the translocation of the long arms of chromosomes 9 and 22 [t(9;22)] in patients with chronic myelogenous leukemia and acute lymphoblastic leukemia (73). The translocation fuses the BCR gene from chromosome 22 and ABL gene from chromosome 9, creating an oncogenic BCR-ABL hybrid gene (Figure 3) (74). The BCR-ABL fusion protein has dramatically increased the tyrosine kinase activity, as compared to that of the normal ABL protein, leading to aberrant phosphorylation of several downstream molecules. The kinase activities of both BCR-ABL and ABL can be inhibited by a specific tyrosine kinase inhibitor, STI 571 (Imatinib®), which is now used in the effective treatment of BCR-ABL-positive leukemia (75, 76). RNAi was also used to target the BCR-ABL mRNA, and this approach was compared to that of STI 571-mediated cell killing in

TABLE 2. SELECTION OF POSSIBLE TARGETS FOR TUMOR THERAPY BY siRNAs

Genes or Fusion Genes	Aberration	Tumors
RAS	Point mutations	Pancreatic carcinoma, chronic leukemia, colon carcinoma, lung cancers
c-MYC, N-MYC	Overexpression, translocation, Point mutation, amplification	Burkitt's lymphoma, neuroblastoma
ERBB	overexpression	Breast cancer
ERBB2	Overexpression	Breast cancer
MLL fusion genes	Translocation	Acute leukemias
BCR-ABL	Translocation	Acute and chronic leukemia
TEL-AML1	Translocation	Childhood acute leukemia
EWS-FLI1	Translocation	Ewing sarcoma
TLS-FUS	Translocation	Myxoid liposarcoma
PAX3-FKHR	Translocation	Alveolar rhabdomyosarcoma
BCL-2	Overexpression, translocation	Lung cancers, Non-Hodgkin lymphoma, prostate cancer
AML1-ETO	Translocation	Acute leukemia

a cell culture model. The siRNA treatment readily reduced the expression of BCR-ABL mRNA, followed by a reduction of BCR-ABL oncoprotein, leading to apoptosis in leukemic cells (77). siRNA-based BCR-ABL silencing may become important considering that some patients develop drug resistance against STI 571 (e.g., by genomic amplification of BCR-ABL, increased expression of BCR-ABL mRNA or point mutation in the ABL gene). Alternative therapies, perhaps applied in combination with inhibitors such as STI 571, may help to overcome problems of such drug resistance.

The combined effort of many laboratories worldwide has led to the molecular clarification of numerous chromosomal translocations through the successful cloning of the genes adjacent to the chromosomal breakpoint regions. Silencing of these tumor-specific, chimeric mRNAs by siRNAs might become an effective fusion gene-specific tumor therapy. The extraordinary sequence specificity of the RNAi mechanism may also allow for the targeting of individual polymorphic alleles expressed in loss-of-heterozygosity tumor cells, as well as targeting point-mutated transcripts of transforming oncogenes such as Ras. Finally, the decrease of overexpressed apoptosis inhibitors such as Bcl-2 and c-Myc might also be beneficial for cancer therapy. A list of possible targets for siRNA-mediated therapy in human malignancies is shown in Table 2.

With respect to future medical applications, siRNAs were recently directed against a mutated mRNA associated with the spinobulbular muscular atrophy (SBMA) in tissue culture (78). SBMA, together with Huntington Disease, belongs to a growing group of neurodegenerative disorders caused by the expansion of trinucleotide repeats (79). Targeting the CAG-expanded mRNA transcript with dsRNA may be an attractive alternative to commonly used therapeutic strategies that, beyond symptomatic treatment, mainly focus on the inhibition of the toxic effects of the polyglutamine protein. Caplen et al. (78) successfully decreased the expression of mutated transcripts of the androgen receptor in human kidney 293T cells that were transfected with a plasmid encoding the expanded-CAG androgen receptor mutant. Most importantly, the authors achieved a rescue of the polyglutamine-induced cytotoxicity in cells treated with dsRNA molecules. Even though the study observed RNAi in transfected cells in vitro rather

than in a more physiologically relevant context, the approach provides proof-of-principle, and underlines the remarkably broad potency and sequence-specificity of RNAi-mediated gene therapy. Whether the RNAi pathway is functionally active in various neuronal cells irrespective of their state of differentiation remains to be shown.

The delivery of siRNAs to the proper sites of therapy remains problematic. This is especially true for their delivery to primary cells, because such cells often do not tolerate treatment with liposome transfection reagents. Chemical modification of siRNAs, such as changing the lipophilicity of the molecule may be considered—for example, phosphorothioate modifications present in antisense oligodeoxynucleotides, or the attachment of lipophilic residues at the 3'-termini of the siRNA duplex. Delivery of siRNAs into organisms might be achieved with methods previously developed for the application of antisense oligonucleotides or nuclease-resistant ribozymes. Such methods consist of the injection of naked or liposome-encapsulated molecules. Studies that inform us about the possibility of exploiting RNAi in various cell types, tissues, and organs are urgently needed. Without doubt, these experiments will be performed in the near future in academic as well as industrial settings.

CONCLUSIONS

The pace with which siRNAs revolutionize the analysis of mammalian gene function is astounding, considering that siRNA-mediated gene silencing was only introduced last year (9, 78). siRNAs are poised to facilitate the genome-wide systematic analysis of gene function in cultured cells, and may soon become a valuable tool for target validation beyond in vitro tissue culture. siRNAs may yet provide a solution for gene-specific drug development, especially before highly specific small-molecule inhibitors become available. 🍀

Acknowledgments

We acknowledge Sayda Elbashir, Jens Harborth, Klaus Weber and Ulrike Krämer for critical comments on the manuscript. Our own studies were made possible by grants from the Deutsche Forschungsgemeinschaft.

References

- Hammond, S.M., Caudy, A.A., and Hannon, G.J. Post-transcriptional gene silencing by double-stranded RNA. *Nat. Rev. Genet.* **2**, 110–119 (2001).
- Hutvagner, G. and Zamore, P.D. RNAi: Nature abhors a double-strand. *Curr. Opin. Genet. Dev.* **12**, 225–232 (2002).
- Sharp, P.A. RNA interference 2001. *Genes Dev.* **15**, 485–490 (2001).
- Waterhouse, P.M., Wang, M.B., and Lough, T. Gene silencing as an adaptive defence against viruses. *Nature* **411**, 834–842 (2001).
- Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., and Mello, C.C. Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. *Nature* **391**, 806–811 (1998).
- Elbashir, S.M., Lendeckel, W., and Tuschl, T. RNA interference is mediated by 21 and 22 nt RNAs. *Genes Dev.* **15**, 188–200 (2001).
- Elbashir, S.M., Martinez, J., Patkaniowska, A., Lendeckel, W., and Tuschl, T. Functional anatomy of


- siRNAs for mediating efficient RNAi in *Drosophila melanogaster* embryo lysate. *EMBO J.* **20**, 6877–6888 (2001).
8. Caplen, N.J., Parrish, S., Imani, F., Fire, A., and Morgan, R.A. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. *Proc. Natl. Acad. Sci. U.S.A.* **98**, 9742–9747 (2001).
 9. Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA interference in mammalian cell culture. *Nature* **411**, 494–498 (2001).
 10. Stark, G.R., Kerr, I.M., Williams, B.R., Silverman, R.H., and Schreiber, R.D. How cells respond to interferons. *Annu. Rev. Biochem.* **67**, 227–264 (1998).
 11. Brummelkamp, T.R., Bernards, R., and Agami, R. A system for stable expression of short interfering RNAs in mammalian cells. *Science* **296**, 550–553 (2002).
 12. Holen, T., Amarzguioui, M., Wiiger, M.T., Babaie, E., and Prydz, H. Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor. *Nucleic Acids Res.* **30**, 1757–1766 (2002).
 13. Flaherty, K.T., Stevenson, J.P., and O'Dwyer, P.J. Antisense therapeutics: Lessons from early clinical trials. *Curr. Opin. Oncol.* **13**, 499–505 (2001).
 14. Bernstein, E., Caudy, A.A., Hammond, S.M., and Hannon, G.J. Role for a bidentate ribonuclease in the initiation step of RNA interference. *Nature* **409**, 363–366 (2001).
 15. Billy, E., Brondani, V., Zhang, H., Muller, U., and Filipowicz, W. Specific interference with gene expression induced by long, double-stranded RNA in mouse embryonal teratocarcinoma cell lines. *Proc. Natl. Acad. Sci. U.S.A.* **98**, 14428–14433 (2001).
 16. Ketting, R.F., Fischer, S.E., Bernstein, E., Sijen, T., Hannon, G.J., and Plasterk, R.H. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in *C. elegans*. *Genes Dev.* **15**, 2654–2659 (2001).
 17. Cerutti, L., Mian, N., and Bateman, A. Domains in gene silencing and cell differentiation proteins: The novel PAZ domain and redefinition of the piwi domain. *Trends Biochem. Sci.* **25**, 481–482 (2000).
 18. Hammond, S.M., Bernstein, E., Beach, D., and Hannon, G.J. An RNA-directed nuclease mediates post-transcriptional gene silencing in *Drosophila* cells. *Nature* **404**, 293–296 (2000).
 19. Williams, R.W. and Rubin, G.M. ARGONAUTE1 is required for efficient RNA interference in *Drosophila* embryos. *Proc. Natl. Acad. Sci. U.S.A.* **99**, 6889–6894 (2002).
 20. Hammond, S.M., Boettcher, S., Caudy, A.A., Kobayashi, R., and Hannon, G.J. Argonaute2, a link between genetic and biochemical analyses of RNAi. *Science* **293**, 1146–1150 (2001).
 21. Nykänen, A., Haley, B., and Zamore, P.D. ATP requirements and small interfering RNA structure in the RNA interference pathway. *Cell* **107**, 309–321 (2001).
 22. Boutla, A., Delidakis, C., Livadaras, I., Tsagris, M., and Tabler, M. Short 5'-phosphorylated double-stranded RNAs induce RNA interference in *Drosophila*. *Curr. Biol.* **11**, 1776–1780 (2001).
 23. Elbashir, S.M., Harborth, J., Weber, K., and Tuschl, T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. *Methods* **26**, 199–213 (2002).
 24. Sijen, T., Fleenor, J., Simmer, F., Thijssen, K.L., Parrish, S., and Timmons, L., Plasterk, R.H., Fire, A. On the role of RNA amplification in dsRNA-triggered gene silencing. *Cell* **107**, 465–476 (2001).
 25. Fraser, A.G., Kamath, R.S., Zipperlen, P., Martinez-Campos, M., Sohrmann, M., and Ahringer, J. Functional genomic analysis of *C. elegans* chromosome I by systematic RNA interference. *Nature* **408**, 325–330 (2000).
 26. Gönczy, P., Echeverri, C., Oegema, K. et al. Functional genomic analysis of cell division in *C. elegans* using RNAi of genes on chromosome III. *Nature* **408**, 331–336 (2000).
 27. Parrish, S., Fleenor, J., Xu, S., Mello, C., and Fire, A. Functional anatomy of a dsRNA trigger: Differential requirement for the two trigger strands in RNA Interference. *Mol. Cell* **6**, 1077–1087 (2000).
 28. Tijsterman, M., Ketting, R.F., Okihara, K.L., and Plasterk, R.H. RNA helicase MUT-14–dependent silencing triggered in *C. elegans* by short antisense RNAs. *Science* **295**, 694–697 (2002).
 29. Lipardi, C., Wei, Q., and Paterson, B.M. RNAi as Random Degradative PCR. siRNA primers convert mRNA into dsRNAs that are degraded to generate new siRNAs. *Cell* **107**, 297–307 (2001).
 30. Kisielow, M., Kleiner, S., Nagasawa, M., Faisal, A., and Nagamine, Y. Isoform-specific knockdown and expression of adaptor protein ShcA using small interfering RNA. *Biochem. J.* **363**, 1–5 (2002).
 31. Zamore, P.D., Tuschl, T., Sharp, P.A., and Bartel, D.P. RNAi: Double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. *Cell* **101**, 25–33 (2000).
 32. Harborth, J., Elbashir, S.M., Beichert, K., Tuschl, T., and Weber, K. Identification of essential genes in cultured mammalian cells using small

- interfering RNAs. *J. Cell Sci.* **114**, 4557–4565 (2001).
33. Caplen, N.J., Fleenor, J., Fire, A., and Morgan, R.A. dsRNA-mediated gene silencing in cultured *Drosophila* cells: A tissue culture model for the analysis of RNA interference. *Gene* **252**, 95–105 (2000).
 34. Clemens, J.C., Worby, C.A., Simonson-Leff, N., Muda, M., Maehama, T., Hemmings, B.A., and Dixon, J.E. Use of double-stranded RNA interference in *Drosophila* cell lines to dissect signal transduction pathways. *Proc. Natl. Acad. Sci. U.S.A.* **97**, 6499–6503 (2000).
 35. Ui-Tei, K., Zenno, S., Miyata, Y., and Saigo, K. Sensitive assay of RNA interference in *Drosophila* and Chinese hamster cultured cells using firefly luciferase gene as target. *FEBS Lett.* **479**, 79–82 (2000).
 36. Svoboda, P., Stein, P., Hayashi, H., and Schultz, R.M. Selective reduction of dormant maternal mRNAs in mouse oocytes by RNA interference. *Development* **127**, 4147–4156 (2000).
 37. Wianny, F. and Zernicka-Goetz, M. Specific interference with gene function by double-stranded RNA in early mouse development. *Nat. Cell Biol.* **2**, 70–75 (2000).
 38. Paddison, P.J., Caudy, A.A., and Hannon, G.J. Stable suppression of gene expression by RNAi in mammalian cells. *Proc. Natl. Acad. Sci. U.S.A.* **99**, 1443–1448 (2002).
 39. Yang, S., Tutton, S., Pierce, E., and Yoon, K. Specific double-stranded RNA interference in undifferentiated mouse embryonic stem cells. *Mol. Cell. Biol.* **21**, 7807–7816 (2001).
 40. Donz , O. and Picard, D. RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase. *Nucleic Acids Res.* **30**, e46 (2002).
 41. Paddison, P.J., Caudy, A.A., Bernstein, E., Hannon, G.J., and Conklin, D.S. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. *Genes Dev.* **16**, 948–958 (2002).
 42. Yu, J.Y., DeRuiter, S.L., and Turner, D.L. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. *Proc. Natl. Acad. Sci. U.S.A.* **99**, 6047–6052 (2002).
 43. Lee, N.S., Dohjima, T., Bauer, G., Li, H., Li, M.J., Ehsani, A., Salvaterra, P., and Rossi, J. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. *Nat. Biotech.* **20**, 500–505 (2002).
 44. Miyagishi, M. and Taira, K. U6 promoter driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells. *Nat. Biotech.* **20**, 497–500 (2002).
 45. Paul, C.P., Good, P.D., Winer, I., and Engelke, D.R. Effective expression of small interfering RNA in human cells. *Nat. Biotech.* **20**, 505–508 (2002).
 46. Sui, G., Soohoo, C., Affar el, B., Gay, F., Shi, Y., and Forrester, W.C. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. *Proc. Natl. Acad. Sci. U.S.A.* **99**, 5515–5520 (2002).
 47. Ziauddin, J. and Sabatini, D.M. Microarrays of cells expressing defined cDNAs. *Nature* **411**, 107–110 (2001).
 48. Garrus, J.E., von Schwedler, U.K., Pornillos, O.W. et al. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. *Cell* **107**, 55–65 (2001).
 49. Cortez, D., Guntuku, S., Qin, J., and Elledge, S.J. ATR and ATRIP: Partners in checkpoint signaling. *Science* **294**, 1713–1716 (2001).
 50. Mailand, N., Lukas, C., Kaiser, B.K., Jackson, P.K., Bartek, J., and Lukas, J. Deregulated human Cdc14A phosphatase disrupts centrosome separation and chromosome segregation. *Nat. Cell Biol.* **4**, 318–322 (2002).
 51. Porter, L.A., Dellinger, R.W., Tynan, J.A., Barnes, E.A., Kong, M., Lenormand, J.L., and Donoghue, D.J. Human Speedy: A novel cell cycle regulator that enhances proliferation through activation of Cdk2. *J. Cell Biol.* **157**, 357–366 (2002).
 52. Stucke, V.M., Sillje, H.H., Arnaud, L., and Nigg, E.A. Human Mps1 kinase is required for the spindle assembly checkpoint but not for centrosome duplication. *EMBO J.* **21**, 1723–1732 (2002).
 53. Zou, L., Cortez, D., and Elledge, S.J. Regulation of ATR substrate selection by Rad17-dependent loading of Rad9 complexes onto chromatin. *Genes Dev.* **16**, 198–208 (2002).
 54. Ancellin, N., Colmont, C., Su, J., Li, Q., Mittereder, N., Chae, S.S., Steffansson, S., Liau, G., and Hla, T. Extracellular export of sphingosine kinase-1 enzyme: Sphingosine 1-phosphate generation and the induction of angiogenic vascular maturation. *J. Biol. Chem.* **277**, 6667–6675 (2001).
 55. Bai, X., Zhou, D., Brown, J.R., Crawford, B.E., Hennet, T., and Esko, J.D. Biosynthesis of the linkage region of glycosaminoglycan: Cloning and activity of galactosyltransferase II, the sixth member of the β 1,3-galactosyltransferase family (β 3GalT6). *J. Biol. Chem.* **276**, 48189–48195 (2001).
 56. Hutv gner, G., McLachlan, J., B lint,  ., Tuschl, T., and Zamore, P.D. A cellular function for the RNA interference enzyme Dicer in small temporal RNA maturation. *Science* **93**, 834–838 (2001).
 57. Habas, R., Kato, Y., and He, X. Wnt/Frizzled activation of Rho regulates vertebrate gastrulation and

- requires a novel Formin homology protein Daam1. *Cell* **107**, 843–854 (2001).
58. Li, L., Mao, J., Sun, L., Liu, W., and Wu, D. Second cysteine-rich domain of Dickkopf-2 activates canonical Wnt signaling pathway via LRP-6 independently of dishevelled. *J. Biol. Chem.* **277**, 5977–5981 (2001).
 59. Martins, L.M., Iaccarino, I., Tenev, T. et al. The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a Reaper-like motif. *J. Biol. Chem.* **277**, 439–444 (2002).
 60. Du, Q., Stukenberg, P.T., and Macara, I.G. A mammalian partner of inscuteable binds NuMA and regulates mitotic spindle organization. *Nat. Cell Biol.* **3**, 1069–1075 (2001).
 61. Moskalenko, S., Henry, D.O., Rosse, C., Mirey, G., Camonis, J.H., and White, M.A. The exocyst is a Ral effector complex. *Nat. Cell Biol.* **4**, 66–72 (2002).
 62. Short, B., Preisinger, C., Korner, R., Kopajtich, R., Byron, O., and Barr, F.A. A GRASP55–rab2 effector complex linking Golgi structure to membrane traffic. *J. Cell Biol.* **155**, 877–883 (2001).
 63. Ostendorff, H.P., Peirano, R.I., Peters, M.A., Schluter, A., Bossenz, M., Scheffner, M., and Bach, I. Ubiquitination-dependent cofactor exchange on LIM homeodomain transcription factors. *Nature* **416**, 99–103 (2002).
 64. Bakker, J., Lin, X., and Nelson, W.G. Methyl-CpG binding domain protein 2 represses transcription from hypermethylated p-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells. *J. Biol. Chem.*, in press. Published April 17, 2002 as 10.1074/jbc.M203009200 (2002).
 65. Guo, H.S. and Ding, S.W. A viral protein inhibits the long range signaling activity of the gene silencing signal. *EMBO J.* **21**, 398–407 (2002).
 66. Kasschau, K.D. and Carrington, J.C. A counterdefensive strategy of plant viruses: Suppression of posttranscriptional gene silencing. *Cell* **95**, 461–470 (1998).
 67. Li, H.W., Lucy, A.P., Guo, H.S., Li, W.X., Ji, L.H., Wong, S.M., and Ding, S.W. Strong host resistance targeted against a viral suppressor of the plant gene silencing defence mechanism. *EMBO J.* **18**, 2683–2691 (1999).
 68. Li, W.X. and Ding, S.W. Viral suppressors of RNA silencing. *Curr. Opin. Biotechnol.* **12**, 150–154 (2001).
 69. Llave, C., Kasschau, K.D., and Carrington, J.C. Virus-encoded suppressor of posttranscriptional gene silencing targets a maintenance step in the silencing pathway. *Proc. Natl. Acad. Sci. U.S.A.* **97**, 13401–13406 (2000).
 70. Lucy, A.P., Guo, H.S., Li, W.X., and Ding, S.W. Suppression of post-transcriptional gene silencing by a plant viral protein localized in the nucleus. *EMBO J.* **19**, 1672–1680 (2000).
 71. Li, H., Li, W.X., and Ding, S.W. Induction and suppression of RNA silencing by an animal virus. *Science* **296**, 1319–1321 (2002).
 72. Bitko, V. and Barik, S. Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. *BMC Microbiol.* **1**, 34 (2001).
 73. Rowley, J.D. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. *Nature* **243**, 290–293 (1973).
 74. de Klein, A., van Kessel, A.G., Grosveld, G. et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. *Nature* **300**, 765–767 (1982).
 75. Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D.J., Reese, S.F., Ford, J.M., Capdeville, R., and Talpaz, M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. *N. Engl. J. Med.* **344**, 1038–1042 (2001).
 76. Druker, B.J., Talpaz, M., Resta, D.J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. *N. Engl. J. Med.* **344**, 1031–1037 (2001).
 77. Wilda, M., Fuchs, U., Wössmann W., and Borkhardt, A., Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). *Oncogene* in press.
 78. Caplen, N.J., Taylor, J.P., Statham, V.S., Tanaka, F., Fire, A., and Morgan, R.A. Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference. *Hum. Mol. Genet.* **11**, 175–184 (2002).
 79. La Spada, A.R., Wilson, E.M., Lubahn, D.B., Harding, A.E., and Fischbeck, K.H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. *Nature* **352**, 77–79 (1991).
 80. Cogoni, C. and Macino, G. Gene silencing in *Neurospora crassa* requires a protein homologous to RNA-dependent RNA polymerase. *Nature* **399**, 166–169 (1999).
 81. Dalmay, T., Hamilton, A., Rudd, S., Angell, S., and Baulcombe, D.C. An RNA-dependent RNA polymerase gene in Arabidopsis is required for posttranscriptional gene silencing mediated by a transgene but not by a virus. *Cell* **101**, 543–553 (2000).
 82. Mourrain, P., Beclin, C., Elmayan, T. et al. Arabidopsis SGS2 and SGS3 genes

are required for posttranscriptional gene silencing and natural virus resistance. *Cell* **101**, 533–542 (2000).

83. Smardon, A., Spoerke, J., Stacey, S., Klein, M., Mackin, N., and Maine, E. EGO-1 is related to RNA-directed RNA polymerase and functions in germ-line development and RNA interference in *C. elegans*. *Curr. Biol.* **10**, 169–178 (2000).
84. Hirai, I. and Wang, H.G. A role of the C-terminal region of hRad9 in nuclear transport of the hRad9-hRad1-hHus1 checkpoint complex. *J. Biol. Chem.*, in press. Published May 6, 2002 as 10.1074/jbc.M203079200 (2002).



Thomas Tuschl, PhD, is an EMBO Young Investigator and leads the Combinatorial Biochemistry Research Group at the Department of Cellular Biochemistry, Max-Planck-Institute for Biophysical Chemistry, Goettingen, Germany. **Arndt Borkhardt, MD**, is a Principal Investigator in the Department of Pediatric Hematology and Oncology, at Children's University Hospital, Giessen, Germany. Address correspondence to either T.T. or A.B. E-mail ttuschl@mpibpc.gwdg.de; e-mail arndt.borkhardt@paediat.med.uni-giessen.de